Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Placebo Controlled Phase Ⅱ Study to Determine the Dosing Interval and the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat

NCT05266729 is registered in ClinicalTrials.gov with AMIpharm Co., Ltd. as lead sponsor.

NCT NCT05266729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Placebo Controlled Phase Ⅱ Study to Determine the Dosing Interval and the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
Lead sponsor
AMIpharm Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2022
Completion date
February 20, 2023
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate or severe submental fullness